Orbuculum

India
AI-based solutions for disease prediction are provided using genomic data.

About Orbuculum

Orbuculum is a Healthcare company based in India by Pranav Gangwal and Faiz Ahmad. AI-based solutions for disease prediction are provided using genomic data. Its chief executive, as recorded, is Pranav Gangwal. Its Indian entity Orbuculum Genolytics Private Limited reported revenue of β‚Ή1.3 Lakh. Its focus areas include Life Sciences, Genomics, Genome Informatics and Integrative Bioinformatics Platforms.

Company details

AI-based solutions for disease prediction are offered by Orbuculum, a company located in India. Genomic data is analyzed to forecast risks for conditions such as cancer, diabetes, neurological disorders, and cardiovascular diseases. The company was co-founded by Pranav Gangwal, serving as CEO, and Faiz Ahmad. Operations center on applying artificial intelligence within the healthcare and genomics sectors to aid in early detection.

Key Metrics
  • Annual Revenue
    ₹1.3 Lakh

    FY 2024 · -82% YoY

  • Net Loss
    -₹5.5 Lakh

    FY 2024 · -437% margin

  • EBITDA
    -₹5.5 Lakh

    FY 2024 · -437% margin

  • Investors

Funding Insights of Orbuculum

  • Total Rounds 1
  • Investors Count 1

All 1 funding rounds of Orbuculum with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Apr 2017Seed––
Valuation history

1 investors in total: 1 institutional.

Investors in Orbuculum

Orbuculum has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Axilor Accelerator.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Tech startups are supported via VC-backed acceleration programs.
axilor.com/acceleratorBengaluru, India
Premium access

Investor details for Orbuculum

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Orbuculum Genolytics Private Limited (Orbuculum)

Orbuculum Genolytics Private Limited is the primary company behind Orbuculum. The board of Orbuculum Genolytics Private Limited currently have 2 directors; the longest-serving is Pranav Gangwal, appointed in 2017. 2 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Pranav Gangwal
DIN 07902045
Director25 Aug 20179 yrs 2 moOrbuculum Genolytics Private Limited
Prafull Kumar Gangwal
DIN 02119335
Director25 Mar 20233 yrs 7 moOrbuculum Genolytics Private Limited

People of Orbuculum

2 people are tracked at Orbuculum (2 in leadership).

NameRoleGroup
Co-Founder & CEOLeadership
Faiz Ahmad
Co-FounderLeadership
Premium access

Complete people profiles for Orbuculum

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Financials of Orbuculum

Figures of Orbuculum Genolytics Private Limited, the primary company behind Orbuculum, for FY 2024. Revenue was ₹1.3 Lakh (-82% year on year). Net loss was -₹5.5 Lakh (-437% margin). EBITDA was -₹5.5 Lakh (-437% margin). Revenue has grown at a compounded annual rate of +6% over three years.

  • ₹1.3 LakhRevenue · FY 2024 · -82% YoY
  • -₹5.5 LakhNet loss · -437% margin
  • -₹5.5 LakhEBITDA · -437% margin
  • ₹1.7 LakhPaid-up capital
  • 34Employees (provident fund records)
  • +6%Revenue CAGR, 3 years

Balance sheet, profit and loss, cash flow and ratios of Orbuculum Genolytics Private Limited are on its company page.

Premium access

Detailed financial statements for Orbuculum

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Orbuculum

Orbuculum is headquartered in India.

Pranav Gangwal is the CEO of Orbuculum, as recorded in our data. They have also founded this company.

The primary company behind Orbuculum, Orbuculum Genolytics Private Limited, reported revenue of β‚Ή1.3 Lakh for FY 2024, down 82% year on year.

AI-based solutions for disease prediction are offered by Orbuculum, a company located in India. Genomic data is analyzed to forecast risks for conditions such as cancer, diabetes, neurological disorders, and cardiovascular diseases. The company was co-founded by Pranav Gangwal, serving as CEO, and Faiz Ahmad. Operations center on applying artificial intelligence within the healthcare and genomics sectors to aid in early detection.

Orbuculum has 1 investor. Key investors include Axilor Accelerator.

Orbuculum operates through Orbuculum Genolytics Private Limited.

The legal entities of Orbuculum currently have 2 directors, including Pranav Gangwal, Prafull Kumar Gangwal.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available